Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report

Anti-synthetase syndrome is a subset of idiopathic inflammatory myopathies, for which refractory disease can be difficult to treat. Daratumumab, an anti-CD38 monoclonal antibody primarily used in hematologic malignancies, has recently shown promise in very few case reports of refractory idiopathic i...

Full description

Saved in:
Bibliographic Details
Main Authors: Nam Nguyen, Valérie Leclair, Rayan Kaedbey, Marie Hudson
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X251336022
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850196452057284608
author Nam Nguyen
Valérie Leclair
Rayan Kaedbey
Marie Hudson
author_facet Nam Nguyen
Valérie Leclair
Rayan Kaedbey
Marie Hudson
author_sort Nam Nguyen
collection DOAJ
description Anti-synthetase syndrome is a subset of idiopathic inflammatory myopathies, for which refractory disease can be difficult to treat. Daratumumab, an anti-CD38 monoclonal antibody primarily used in hematologic malignancies, has recently shown promise in very few case reports of refractory idiopathic inflammatory myopathies. We present a case of a 44-year-old man with anti-Jo1 anti-synthetase syndrome with concurrent anti-Ro52, in which myositis remained refractory to multiple immunosuppressants. Despite treatment with daratumumab, the patient did not respond and ultimately succumbed to infection. This case underscores the need for further research to better define the role of daratumumab in idiopathic inflammatory myopathies and identify predictors of treatment response.
format Article
id doaj-art-80a8ff56f20743b2afd915aff805671a
institution OA Journals
issn 2050-313X
language English
publishDate 2025-04-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medical Case Reports
spelling doaj-art-80a8ff56f20743b2afd915aff805671a2025-08-20T02:13:27ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-04-011310.1177/2050313X251336022Failure of daratumumab in the treatment of anti-synthetase syndrome: A case reportNam Nguyen0Valérie Leclair1Rayan Kaedbey2Marie Hudson3Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, CanadaDivision of Rheumatology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, CanadaDivision of Hematology, Jewish General Hospital, Montreal, QC, CanadaDivision of Rheumatology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, CanadaAnti-synthetase syndrome is a subset of idiopathic inflammatory myopathies, for which refractory disease can be difficult to treat. Daratumumab, an anti-CD38 monoclonal antibody primarily used in hematologic malignancies, has recently shown promise in very few case reports of refractory idiopathic inflammatory myopathies. We present a case of a 44-year-old man with anti-Jo1 anti-synthetase syndrome with concurrent anti-Ro52, in which myositis remained refractory to multiple immunosuppressants. Despite treatment with daratumumab, the patient did not respond and ultimately succumbed to infection. This case underscores the need for further research to better define the role of daratumumab in idiopathic inflammatory myopathies and identify predictors of treatment response.https://doi.org/10.1177/2050313X251336022
spellingShingle Nam Nguyen
Valérie Leclair
Rayan Kaedbey
Marie Hudson
Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report
SAGE Open Medical Case Reports
title Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report
title_full Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report
title_fullStr Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report
title_full_unstemmed Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report
title_short Failure of daratumumab in the treatment of anti-synthetase syndrome: A case report
title_sort failure of daratumumab in the treatment of anti synthetase syndrome a case report
url https://doi.org/10.1177/2050313X251336022
work_keys_str_mv AT namnguyen failureofdaratumumabinthetreatmentofantisynthetasesyndromeacasereport
AT valerieleclair failureofdaratumumabinthetreatmentofantisynthetasesyndromeacasereport
AT rayankaedbey failureofdaratumumabinthetreatmentofantisynthetasesyndromeacasereport
AT mariehudson failureofdaratumumabinthetreatmentofantisynthetasesyndromeacasereport